Celularity (NASDAQ:CELU) Reaches New 12-Month Low at $3.40

Celularity Inc. (NASDAQ:CELUGet Rating) shares hit a new 52-week low during trading on Thursday . The company traded as low as $3.40 and last traded at $3.47, with a volume of 1224632 shares changing hands. The stock had previously closed at $3.78.

Several brokerages have weighed in on CELU. Truist Financial lowered Celularity from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a report on Wednesday, April 6th. HC Wainwright initiated coverage on Celularity in a report on Wednesday. They set a “buy” rating for the company. Finally, Oppenheimer raised their price target on Celularity from $9.00 to $10.00 in a report on Friday, April 1st.

The firm has a 50 day moving average price of $8.43 and a 200 day moving average price of $6.92.

Celularity (NASDAQ:CELUGet Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.25). The company had revenue of $5.94 million during the quarter, compared to analysts’ expectations of $5.16 million. Celularity had a negative return on equity of 136.80% and a negative net margin of 330.93%. As a group, analysts forecast that Celularity Inc. will post -1.33 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. LMR Partners LLP purchased a new position in shares of Celularity in the 4th quarter worth approximately $173,000. Marshall Wace LLP bought a new stake in shares of Celularity in the 3rd quarter worth about $87,000. BlackRock Inc. purchased a new position in shares of Celularity during the 3rd quarter worth about $179,000. Verition Fund Management LLC purchased a new stake in Celularity in the 3rd quarter worth about $354,000. Finally, Qube Research & Technologies Ltd bought a new stake in Celularity in the first quarter worth about $238,000. Hedge funds and other institutional investors own 12.13% of the company’s stock.

Celularity Company Profile (NASDAQ:CELU)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.